 Predictive Oncology Inc. NASDAQ:POAI has reported revenue growth and an increased gross profit margin in its third quarter as the company continues to gain traction with potential partners with its breakthrough solution at a pivotal time in drug discovery. The company said during the quarter it leveraged its novel artificial intelligence-powered platform paired with the largest privately held biobank of over 150,000 tumor samples to help drug developers make higher confidence predictions of which molecules will and wont be successful, and ultimately leading to greater chances of commercial success. 